loading
Precedente Chiudi:
$0.269
Aprire:
$0.27
Volume 24 ore:
295.41K
Relative Volume:
0.14
Capitalizzazione di mercato:
$55.38M
Reddito:
$74,000
Utile/perdita netta:
$-13.43M
Rapporto P/E:
-0.0261
EPS:
-9.4
Flusso di cassa netto:
$-10.54M
1 W Prestazione:
-19.45%
1M Prestazione:
-26.03%
6M Prestazione:
-73.63%
1 anno Prestazione:
-88.43%
Intervallo 1D:
Value
$0.2215
$0.27
Intervallo di 1 settimana:
Value
$0.2215
$0.3177
Portata 52W:
Value
$0.2215
$4.00

Cyclacel Pharmaceuticals Inc Stock (CYCC) Company Profile

Name
Nome
Cyclacel Pharmaceuticals Inc
Name
Telefono
908-517-7330
Name
Indirizzo
200 CONNELL DRIVE, BERKELEY HEIGHTS, NJ
Name
Dipendente
0
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-11
Name
Ultimi documenti SEC
Name
CYCC's Discussions on Twitter

Confronta CYCC con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
CYCC
Cyclacel Pharmaceuticals Inc
0.2452 55.38M 74,000 -13.43M -10.54M -9.40
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
483.49 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
625.60 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
583.62 35.60B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
266.83 34.53B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
274.78 29.15B 3.81B -644.79M -669.77M -6.24

Cyclacel Pharmaceuticals Inc Stock (CYCC) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2022-07-18 Ripresa Oppenheimer Outperform
2020-04-27 Ripresa ROTH Capital Buy
2018-09-07 Iniziato Ladenburg Thalmann Buy
2015-10-16 Iniziato H.C. Wainwright Buy
2010-02-04 Iniziato Roth Capital Buy
2009-10-28 Iniziato Merriman Buy
2008-08-12 Iniziato Piper Jaffray Buy
2008-03-12 Reiterato Cantor Fitzgerald Buy
2008-03-12 Reiterato Collins Stewart Buy
2008-03-12 Reiterato Needham & Co Buy
2007-11-27 Reiterato Cantor Fitzgerald Buy
2007-08-10 Reiterato Cantor Fitzgerald Buy
2007-06-04 Reiterato Needham & Co Buy
2007-04-23 Iniziato Lazard Capital Buy
2007-04-10 Iniziato Cantor Fitzgerald Buy
Mostra tutto

Cyclacel Pharmaceuticals Inc Borsa (CYCC) Ultime notizie

pulisher
12:41 PM

Cyclacel Pharmaceuticals Shifts Focus to Cancer Drug Development - TipRanks

12:41 PM
pulisher
Apr 02, 2025

Cyclacel Pharmaceuticals, Inc. SEC 10-K Report - TradingView

Apr 02, 2025
pulisher
Apr 02, 2025

Cyclacel Pharmaceuticals Appoints New Directors Amid Strategic Shift - TipRanks

Apr 02, 2025
pulisher
Apr 02, 2025

Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results And Provides Business Update - MarketScreener

Apr 02, 2025
pulisher
Apr 02, 2025

Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update - The Manila Times

Apr 02, 2025
pulisher
Apr 02, 2025

Cyclacel Slashes Net Loss in Half, Streamlines to Focus on Promising Cancer Drug - Stock Titan

Apr 02, 2025
pulisher
Mar 31, 2025

Cyclacel Pharmaceuticals Delays 10-K Filing - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

CYCC stock touches 52-week low at $0.29 amid sharp annual decline By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

CYCC stock touches 52-week low at $0.29 amid sharp annual decline - Investing.com

Mar 31, 2025
pulisher
Mar 31, 2025

StockNews.com Initiates Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC) - Defense World

Mar 31, 2025
pulisher
Mar 31, 2025

Financial Contrast: Cellectar Biosciences (NASDAQ:CLRB) versus Cyclacel Pharmaceuticals (NASDAQ:CYCC) - Defense World

Mar 31, 2025
pulisher
Mar 26, 2025

Cyclacel Pharmaceuticals to offer convertible preferred stock in private placement - MSN

Mar 26, 2025
pulisher
Mar 24, 2025

Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering Of Convertible Preferred Stock - Marketscreener.com

Mar 24, 2025
pulisher
Mar 24, 2025

Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock - The Manila Times

Mar 24, 2025
pulisher
Mar 24, 2025

Cyclacel's Latest $1M Financing Deal Reveals Extended Survival Strategy Through Q3 2025 - Stock Titan

Mar 24, 2025
pulisher
Mar 23, 2025

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by Analysts at StockNews.com - Defense World

Mar 23, 2025
pulisher
Mar 17, 2025

Cyclacel Pharmaceuticals’ Change of Control Transaction and Appointment of New Executive Leadership - Global Legal Chronicle

Mar 17, 2025
pulisher
Mar 17, 2025

(CYCCP) Trading Advice - news.stocktradersdaily.com

Mar 17, 2025
pulisher
Mar 16, 2025

Cyclacel Pharmaceuticals (CYCC) Projected to Post Earnings on Tuesday - The AM Reporter

Mar 16, 2025
pulisher
Mar 15, 2025

CYCLACEL PHARMACEUTICALS Earnings Preview: Recent $CYCC Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 15, 2025
pulisher
Mar 15, 2025

StockNews.com Begins Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC) - Defense World

Mar 15, 2025
pulisher
Mar 14, 2025

Cyclacel Pharmaceuticals acquires cancer drug assets By Investing.com - Investing.com Australia

Mar 14, 2025
pulisher
Mar 14, 2025

Cyclacel Pharmaceuticals acquires cancer drug assets - Investing.com

Mar 14, 2025
pulisher
Mar 12, 2025

Cyclacel stock plunges to 52-week low at $0.3 amid market challenges - Investing.com Australia

Mar 12, 2025
pulisher
Mar 12, 2025

Cyclacel stock plunges to 52-week low at $0.3 amid market challenges By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 11, 2025

Cyclacel Pharmaceuticals (CYCC) to Release Earnings on Tuesday - Defense World

Mar 11, 2025
pulisher
Mar 09, 2025

Cyclacel stock plunges to 52-week low of $0.31 amid market challenges - MSN

Mar 09, 2025
pulisher
Mar 07, 2025

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated at StockNews.com - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

Cyclacel Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Feb 28, 2025

Cyclacel Pharmaceuticals interim CEO David Lazar sells $5.5 million in stock - Investing.com India

Feb 28, 2025
pulisher
Feb 27, 2025

Cyclacel Pharmaceuticals Announces New Leadership and Restructuring - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Cyclacel Pharmaceuticals Says Datuk Dr.Doris Wong Sing Ee Elected As CEO & Executive Director - Marketscreener.com

Feb 27, 2025
pulisher
Feb 27, 2025

Cyclacel Pharmaceuticals Expands Executive Leadership Team - citybiz

Feb 27, 2025
pulisher
Feb 27, 2025

Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership - The Manila Times

Feb 27, 2025
pulisher
Feb 27, 2025

Investor Network: Cyclacel Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

Who Now Controls Cyclacel? New Investor Takes 70% Ownership in $6.3M Leadership Overhaul - StockTitan

Feb 27, 2025
pulisher
Feb 26, 2025

Buffett’s on the Sidelines – Should You Follow? - The Globe and Mail

Feb 26, 2025
pulisher
Feb 24, 2025

Spiro Rombotis, CEO of Cyclacel Pharmaceuticals, on Innovative Targeted Therapies for Advanced - DocWire News

Feb 24, 2025
pulisher
Feb 24, 2025

Cyclacel Pharmaceuticals amends agreement with CEO By Investing.com - Investing.com Australia

Feb 24, 2025
pulisher
Feb 24, 2025

Cyclacel Pharmaceuticals amends agreement with CEO - Investing.com

Feb 24, 2025
pulisher
Feb 24, 2025

(CYCCP) Trading Report - news.stocktradersdaily.com

Feb 24, 2025
pulisher
Feb 23, 2025

Head-To-Head Review: Cyclacel Pharmaceuticals (NASDAQ:CYCC) vs. Silence Therapeutics (NASDAQ:SLN) - Defense World

Feb 23, 2025
pulisher
Feb 17, 2025

Cyclacel Pharmaceuticals, Inc. announced that it expects to receive $25 million in funding from Helena Special Opportunities LLC - Marketscreener.com

Feb 17, 2025
pulisher
Feb 16, 2025

Cyclacel Pharmaceuticals streamlines operations, plans asset purchase - MSN

Feb 16, 2025

Cyclacel Pharmaceuticals Inc Azioni (CYCC) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$73.44
price up icon 2.00%
$68.32
price up icon 0.56%
$31.28
price up icon 0.35%
$20.46
price up icon 8.83%
$93.32
price up icon 3.36%
biotechnology ONC
$274.78
price up icon 1.38%
Capitalizzazione:     |  Volume (24 ore):